{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:27:25Z","timestamp":1792020445108,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"crossref","award":["RR000039"],"award-info":[{"award-number":["RR000039"]}],"id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"crossref","award":["RR00585"],"award-info":[{"award-number":["RR00585"]}],"id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"crossref","award":["RR23940"],"award-info":[{"award-number":["RR23940"]}],"id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"crossref","award":["RR000052"],"award-info":[{"award-number":["RR000052"]}],"id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NCRR CTSAs","award":["RR025008"],"award-info":[{"award-number":["RR025008"]}]},{"name":"NCRR CTSAs","award":["RR024150"],"award-info":[{"award-number":["RR024150"]}]},{"name":"NCRR CTSAs","award":["RR033179"],"award-info":[{"award-number":["RR033179"]}]},{"name":"NCRR CTSAs","award":["RR025777"],"award-info":[{"award-number":["RR025777"]}]},{"name":"NCRR CTSAs","award":["RR024153"],"award-info":[{"award-number":["RR024153"]}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1053\/j.ajkd.2012.08.038","type":"journal-article","created":{"date-parts":[[2012,10,22]],"date-time":"2012-10-22T19:31:24Z","timestamp":1350934284000},"page":"420-429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"title":["Relationship of Copeptin, a Surrogate Marker for Arginine Vasopressin, With Change in Total Kidney Volume and GFR Decline in Autosomal Dominant Polycystic Kidney Disease: Results From the CRISP Cohort"],"prefix":"10.1053","volume":"61","author":[{"given":"Wendy E.","family":"Boertien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Bost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Struck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Flessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron T.","family":"Gansevoort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente E.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9569","key":"10.1053\/j.ajkd.2012.08.038_bib1","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"10.1053\/j.ajkd.2012.08.038_bib2","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1523-1755.2004.00843.x","article-title":"Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells","volume":"66","author":"Belibi","year":"2004","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2012.08.038_bib3","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1046\/j.1523-1755.2003.00242.x","article-title":"Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease","volume":"64","author":"Grantham","year":"2003","journal-title":"Kidney Int"},{"issue":"9","key":"10.1053\/j.ajkd.2012.08.038_bib4","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1172\/JCI107423","article-title":"Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma","volume":"52","author":"Robertson","year":"1973","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1053\/j.ajkd.2012.08.038_bib5","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1373\/clinchem.2005.060038","article-title":"Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin","volume":"52","author":"Morgenthaler","year":"2006","journal-title":"Clin Chem"},{"issue":"2","key":"10.1053\/j.ajkd.2012.08.038_bib6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.tem.2007.11.001","article-title":"Copeptin: clinical use of a new biomarker","volume":"19","author":"Morgenthaler","year":"2008","journal-title":"Trends Endocrinol Metab"},{"issue":"10","key":"10.1053\/j.ajkd.2012.08.038_bib7","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1210\/jc.2007-0232","article-title":"Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects","volume":"92","author":"Szinnai","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1053\/j.ajkd.2012.08.038_bib8","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2215\/CJN.04560510","article-title":"Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease","volume":"6","author":"Meijer","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2012.08.038_bib9","doi-asserted-by":"crossref","unstructured":"Boertien WE, Meijer E, Zittema D, et al. Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease [published ahead of print April 20, 2012]. Nephrol Dial Transplant. doi:10.1093\/ndt\/gfs070.","DOI":"10.1093\/ndt\/gfs070"},{"issue":"3","key":"10.1053\/j.ajkd.2012.08.038_bib10","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1523-1755.2003.00185.x","article-title":"Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort","volume":"64","author":"Chapman","year":"2003","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2012.08.038_bib11","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2215\/CJN.00330705","article-title":"Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes","volume":"1","author":"Grantham","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2012.08.038_bib12","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1046\/j.1523-1755.2003.00326.x","article-title":"Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease","volume":"64","author":"King","year":"2003","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2012.08.038_bib13","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1681\/ASN.2005070697","article-title":"Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the Consortium of Radiologic Imaging Studies of Polycystic Kidney Disease cohort","volume":"17","author":"Rule","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2012.08.038_bib14","doi-asserted-by":"crossref","first-page":"640","DOI":"10.2215\/CJN.03250410","article-title":"Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease","volume":"6","author":"Torres","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8901","key":"10.1053\/j.ajkd.2012.08.038_bib15","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(94)92026-5","article-title":"Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1","volume":"343","author":"Ravine","year":"1994","journal-title":"Lancet"},{"issue":"1","key":"10.1053\/j.ajkd.2012.08.038_bib16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1210\/jc.2008-1426","article-title":"Copeptin in the differential diagnosis of hyponatremia","volume":"94","author":"Fenske","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.ajkd.2012.08.038_bib17","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1681\/ASN.2006060601","article-title":"Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging","volume":"17","author":"Marckmann","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"suppl 7","key":"10.1053\/j.ajkd.2012.08.038_bib18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/ndt\/16.suppl_7.57","article-title":"Identification of patients and risk factors in chronic kidney disease\u2014evaluating risk factors and therapeutic strategies","volume":"16","author":"Levin","year":"2001","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.ajkd.2012.08.038_bib19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ki.2009.397","article-title":"Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort","volume":"77","author":"Meijer","year":"2010","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2012.08.038_bib20","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/TP.0b013e3181b11ae4","article-title":"Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients","volume":"88","author":"Meijer","year":"2009","journal-title":"Transplantation"},{"issue":"6","key":"10.1053\/j.ajkd.2012.08.038_bib21","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2215\/CJN.11311111","article-title":"Vasopressin, copeptin and renal concentrating capacity in ADPKD patients without renal impairment","volume":"7","author":"Zittema","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2012.08.038_bib22","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.2215\/CJN.00360110","article-title":"Early renal abnormalities in autosomal dominant polycystic kidney disease","volume":"5","author":"Meijer","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2012.08.038_bib23","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1053\/j.ajkd.2003.12.026","article-title":"Patients with autosomal dominant polycystic kidney disease hyperfiltrate early in their disease","volume":"43","author":"Wong","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1053\/j.ajkd.2012.08.038_bib24","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1093\/ndt\/gfr069","article-title":"Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug","volume":"26","author":"Meijer","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2012.08.038_bib25","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1681\/ASN.2004121090","article-title":"Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat","volume":"16","author":"Wang","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2012.08.038_bib26","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease","volume":"10","author":"Torres","year":"2004","journal-title":"Nat Med"},{"issue":"10","key":"10.1053\/j.ajkd.2012.08.038_bib27","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat Med"},{"issue":"8","key":"10.1053\/j.ajkd.2012.08.038_bib28","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1681\/ASN.2006030251","article-title":"Increased water intake decreases progression of polycystic kidney disease in the PCK rat","volume":"17","author":"Nagao","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2012.08.038_bib29","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2215\/CJN.03530411","article-title":"Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience","volume":"6","author":"Higashihara","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2012.08.038_bib30","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1053\/j.ajkd.2010.11.029","article-title":"Rationale and design of the TEMPO 3\/4 study, Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes","volume":"57","author":"Torres","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2012.08.038_bib31","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ki.2011.119","article-title":"Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease","volume":"80","author":"Irazabal","year":"2011","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2012.08.038_bib32","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","article-title":"Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease","volume":"68","author":"Ruggenenti","year":"2005","journal-title":"Kidney Int"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638612012279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638612012279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T02:04:57Z","timestamp":1759457097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638612012279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0272638612012279"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2012.08.038","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationship of Copeptin, a Surrogate Marker for Arginine Vasopressin, With Change in Total Kidney Volume and GFR Decline in Autosomal Dominant Polycystic Kidney Disease: Results From the CRISP Cohort","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2012.08.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}